AHNAK2 is over-expressed in several types of cancer, including clear cell renal cell carcinoma, pancreatic ductal adenocarcinoma, uveal melanoma, papillary thyroid carcinoma, and lung adenocarcinoma, where its high expression levels have been linked to poor patient prognosis [21–25]. Here, AHNAK2 is linked to thyroid gland papillary carcinoma.